{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T08:59:20Z","timestamp":1781686760495,"version":"3.54.5"},"reference-count":91,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T00:00:00Z","timestamp":1781654400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Venous Thrombosis is a frequent and clinically significant complication in lymphoma patients, resulting in increased morbidity, mortality and therapeutic challenges. The pathophysiological mechanisms underlying lymphoma-associated thrombosis are multifactorial, involving patients\u2019 clinical characteristics, tumour biology, systemic inflammation, endothelial dysfunction and therapy-induced prothrombotic changes. Traditional predictive tools for cancer-associated thrombosis (CAT) have shown suboptimal application in lymphoma patients due to disease-specific heterogeneity. The ThroLy score was developed as a lymphoma-specific model incorporating parameters such as extranodal involvement, mediastinal disease, performance status, a prior venous thromboembolic event, and specific laboratory values. While it shows improved predictive value compared with general CAT models, its accuracy remains limited, particularly across different lymphoma subtypes and treatment regimens. Research in the field has therefore focused on evaluating emerging biomarkers\u2014D-dimer, microparticles and inflammatory cytokines\u2014as risk assessment tools. Integrative approaches that combine clinical variables with such biomarkers may yield a more dynamic and individualised risk-prediction model to guide thromboprophylactic strategies. The present review summarises current knowledge on thrombotic risk assessment across lymphoma subtypes and highlights the potential role of novel biomarkers in developing a more precise approach to thrombosis prevention and management. Importantly, it provides a comprehensive overview of currently available literature, highlighting the need for personalised thrombosis risk stratification strategies in lymphoma.<\/jats:p>","DOI":"10.3390\/ijms27125461","type":"journal-article","created":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T08:22:56Z","timestamp":1781684576000},"page":"5461","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Risk Assessment for Venous Thrombosis in Lymphoma and Emerging Biomarkers"],"prefix":"10.3390","volume":"27","author":[{"given":"Alexia","family":"Piperidou","sequence":"first","affiliation":[{"name":"Department of Hematology and Bone Marrow Transplantation, Medical School, National and Kapodistrian University of Athens, General Hospital of Athens \u201cLaikon\u201d, 11527 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panagiota-Efstathia","family":"Nikolaou","sequence":"additional","affiliation":[{"name":"Laboratory of Pharmacology, School of Pharmacy, National and Kapodistrian University of Athens, 15771 Athens, Greece"},{"name":"Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, 11527 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0618-8900","authenticated-orcid":false,"given":"Despina","family":"Fotiou","sequence":"additional","affiliation":[{"name":"Clinic & Laboratory of Pathophysiology, Department of Medicine, School of Health Sciences, National and Kapodistrian University of Athens, 5 Mikras Asias Street, 11527 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,6,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.clml.2014.05.003","article-title":"Thrombosis and hemostatic abnormalities in hematological malignancies","volume":"14","author":"Colombo","year":"2014","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1093\/annonc\/mdz168","article-title":"Thrombosis as a treatment complication in Hodgkin lymphoma patients: A comprehensive analysis of three prospective randomized German Hodgkin Study Group (GHSG) trials","volume":"30","author":"Borchmann","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_3","first-page":"5","article-title":"Prediction of venous thromboembolism in newly diagnosed patients treated for lymphoid malignancies: Validation of the Khorana Risk Score","volume":"35","author":"Gil","year":"2017","journal-title":"Med. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/j.amjmed.2010.05.021","article-title":"Incidence and risk factors of venous thromboembolic events in lymphoma","volume":"123","author":"Zhou","year":"2010","journal-title":"Am. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"5322","DOI":"10.1182\/blood-2010-01-258624","article-title":"Thrombotic complications in adult patients with lymphoma: A meta-analysis of 29 independent cohorts including 18 018 patients and 1149 events","volume":"115","author":"Caruso","year":"2010","journal-title":"Blood"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1016\/S0049-3848(14)50004-7","article-title":"Lymphoma and venous thromboembolism: Influence on mortality","volume":"133","author":"Mahajan","year":"2014","journal-title":"Thromb. Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.thromres.2010.08.017","article-title":"Increased risk of venous thromboembolism in patients with primary mediastinal large B-cell lymphoma","volume":"126","author":"Lekovic","year":"2010","journal-title":"Thromb. Res."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1002\/cncr.11623","article-title":"High incidence of thromboembolism in patients with central nervous system lymphoma","volume":"98","author":"Goldschmidt","year":"2003","journal-title":"Cancer"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.thromres.2016.05.008","article-title":"Incidence of venous thromboembolism in patients with non-Hodgkin lymphoma","volume":"143","author":"Sanfilippo","year":"2016","journal-title":"Thromb. Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1160\/TH16-11-0895","article-title":"Khorana score and histotype predicts incidence of early venous thromboembolism in non-Hodgkin lymphomas. A pooled-data analysis of 12 clinical trials of Fondazione Italiana Linfomi (FIL)","volume":"117","author":"Santi","year":"2017","journal-title":"Thromb. Haemost."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.thromres.2015.09.001","article-title":"Incidence, determinants and the transient impact of cancer treatments on venous thromboembolism risk among lymphoma patients in Denmark","volume":"136","author":"Lund","year":"2015","journal-title":"Thromb. Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/s41408-018-0096-1","article-title":"Risk factors for venous thromboembolism in patients with lymphoma requiring hospitalization","volume":"8","author":"Hohaus","year":"2018","journal-title":"Blood Cancer J."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e6","DOI":"10.1016\/j.thromres.2012.03.019","article-title":"Incidence, risk factors and clinical features of venous thromboembolism in newly diagnosed lymphoma patients: Results from a prospective cohort study with Asian population","volume":"130","author":"Park","year":"2012","journal-title":"Thromb. Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.thromres.2019.10.002","article-title":"Incidence and characteristics of venous thromboembolism in Asian patients with primary central nervous system lymphoma undergoing chemotherapy","volume":"183","author":"Byun","year":"2019","journal-title":"Thromb. Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"312","DOI":"10.4143\/crt.2014.266","article-title":"Cross-sectional Study of Patients with Diffuse Large B-Cell Lymphoma: Assessing the Effect of Host Status, Tumor Burden, and Inflammatory Activity on Venous Thromboembolism","volume":"48","author":"Lim","year":"2016","journal-title":"Cancer Res. Treat."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"35404","DOI":"10.18632\/oncotarget.8639","article-title":"High risk of deep vein thrombosis associated with peripherally inserted central catheters in lymphoma","volume":"7","author":"Zhang","year":"2016","journal-title":"Oncotarget"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1016\/j.thromres.2014.08.021","article-title":"Lupus anticoagulant and thrombosis in splenic marginal zone lymphoma","volume":"134","author":"Gebhart","year":"2014","journal-title":"Thromb. Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.thromres.2011.09.022","article-title":"Incidence and risk factors for developing venous thromboembolism in Japanese with diffuse large b-cell lymphoma","volume":"130","author":"Yokoyama","year":"2012","journal-title":"Thromb. Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1080\/10428194.2026.2644580","article-title":"Predictors and timing of venous thromboembolism and overall survival in lymphoma","volume":"67","author":"Trabolsi","year":"2026","journal-title":"Leuk. Lymphoma"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2868","DOI":"10.1002\/cam4.1540","article-title":"Evaluation of the ThroLy score for the prediction of venous thromboembolism in newly diagnosed patients treated for lymphoid malignancies in clinical practice","volume":"7","author":"Gil","year":"2018","journal-title":"Cancer Med."},{"key":"ref_21","first-page":"128","article-title":"Cancer and thrombosis","volume":"24","author":"Donati","year":"1994","journal-title":"Pathophysiol. Haemost. Thromb."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1002\/ajh.24466","article-title":"Development and validation of multivariable predictive model for thromboembolic events in lymphoma patients","volume":"91","author":"Antic","year":"2016","journal-title":"Am. J. Hematol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"4902","DOI":"10.1182\/blood-2007-10-116327","article-title":"Development and validation of a predictive model for chemotherapy-associated thrombosis","volume":"111","author":"Khorana","year":"2008","journal-title":"Blood"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Hohaus, S., Bartolomei, F., Cuccaro, A., Maiolo, E., Alma, E., D\u2019Alo, F., Bellesi, S., Rossi, E., and De Stefano, V. (2020). Venous Thromboembolism in Lymphoma: Risk Stratification and Antithrombotic Prophylaxis. Cancers, 12.","DOI":"10.3390\/cancers12051291"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2771","DOI":"10.1080\/10428194.2016.1185782","article-title":"Incidence of venous thromboembolism in patients with diffuse large B-cell lymphoma","volume":"57","author":"Borg","year":"2016","journal-title":"Leuk. Lymphoma"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1182\/bloodadvances.2018023895","article-title":"Venous thromboembolism in chronic lymphocytic leukemia: A Danish nationwide cohort study","volume":"2","author":"Gade","year":"2018","journal-title":"Blood Adv."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"(1993). International Non-Hodgkin\u2019s Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin\u2019s lymphoma. N. Engl. J. Med., 329, 987\u2013994.","DOI":"10.1056\/NEJM199309303291402"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1080\/10428190600560991","article-title":"Venous thromboembolism in patients with diffuse large B-cell lymphoma","volume":"47","author":"Komrokji","year":"2006","journal-title":"Leuk. Lymphoma"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1002\/cncr.34210","article-title":"Venous-thromboembolism and associated health care utilization in elderly patients with diffuse large B cell lymphoma","volume":"128","author":"Gangaraju","year":"2022","journal-title":"Cancer"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Li, W., Liu, R., Shen, Y., Gao, G., Yang, R., Wang, Y., Yang, R., Lin, Z., Dong, R., and Zhao, W. (2024). Incidence, Risk Factors, and Modified Risk Assessment Model of Venous Thromboembolism in Non-Hodgkin Lymphoma Patients. Cancer Med., 13.","DOI":"10.1002\/cam4.70510"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.blre.2017.10.002","article-title":"Venous thromboembolic events in lymphoma patients: Actual relationships between epidemiology, mechanisms, clinical profile and treatment","volume":"32","author":"Antic","year":"2018","journal-title":"Blood Rev."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.semarthrit.2005.07.003","article-title":"Antiphospholipid antibodies associated with malignancies: Clinical and pathological characteristics of 120 patients","volume":"35","author":"Cervera","year":"2006","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1034\/j.1600-0609.2002.01526.x","article-title":"Prevalence and clinical significance of anticardiolipin and anti-\u03b22-glycoprotein-I antibodies in patients with non-Hodgkin\u2019s lymphoma","volume":"68","author":"Genvresse","year":"2002","journal-title":"Eur. J. Haematol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1007\/s11239-024-02977-0","article-title":"Comprehensive evaluation of genetic and acquired thrombophilia markers for an individualized prediction of clinical thrombosis in patients with lymphoma and multiple myeloma","volume":"57","year":"2024","journal-title":"J. Thromb. Thrombolysis"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"100065","DOI":"10.1016\/j.bvth.2025.100065","article-title":"Real-world analysis of strategies to prevent thrombosis and bleeding in adults with ALL treated with asparaginase","volume":"2","author":"Mort","year":"2025","journal-title":"Blood Vessel. Thromb. Hemost."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Pelland-Marcotte, M.C., Ethier, C., Manirakiza, A., Perrault, H., Trombino, E., Laverdiere, C., Nava, T., Theoret, Y., Leclerc, J.M., and Whitlock, J.A. (2026). Asparaginase activity levels and toxicity in children and adolescents with acute lymphoblastic leukemia. Leuk. Lymphoma, 1\u20138.","DOI":"10.1080\/10428194.2026.2656726"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s00262-026-04380-5","article-title":"Hematological toxicities and thrombosis risk associated with immune checkpoint inhibitors: A pharmacovigilance study from 2014 to 2024","volume":"75","author":"Hou","year":"2026","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Ilari, A., Abbate, M.I., Verso, M., Graziani, M., Cafaro, P., Sala, L., Colonese, F., Cortinovis, D.L., and Canova, S. (2026). Cancer-Associated Thrombosis in Patients Treated with Immune Checkpoint Inhibitors. Int. J. Mol. Sci., 27.","DOI":"10.3390\/ijms27041874"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Demosthenous, C., Evangelidis, P., Gatsis, A., Mitroulis, I., Vakalopoulou, S., Vardi, A., Bountoura, S., Sakellari, I., and Gavriilaki, E. (2025). Endothelial Injury Following CAR-T Cell Immunotherapy for Hematological Malignancies. Cancers, 17.","DOI":"10.3390\/cancers17172876"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1111\/bjh.19583","article-title":"Coagulation abnormalities associated with CAR-T-cell therapy in haematological malignancies: A review","volume":"205","author":"Peng","year":"2024","journal-title":"Br. J. Haematol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1111\/bjh.70029","article-title":"Differential modulation of Bruton\u2019s tyrosine kinase inhibitor selectivity on platelet GPVI and integrin \u03b1IIb\u03b23 bidirectional signalling via BTK\/PLC\u03b32\/PKC\u03b8 affects haemostasis and thrombosis","volume":"207","author":"Zhang","year":"2025","journal-title":"Br. J. Haematol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/bjh.16209","article-title":"Venous and arterial thrombosis in patients with haematological malignancy during treatment with ibrutinib","volume":"187","author":"Kander","year":"2019","journal-title":"Br. J. Haematol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1182\/bloodadvances.2018016683","article-title":"Venous thromboembolism in patients with B-cell non-Hodgkin lymphoma treated with lenalidomide: A systematic review and meta-analysis","volume":"2","author":"Yamshon","year":"2018","journal-title":"Blood Adv."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"e038782","DOI":"10.1161\/JAHA.124.038782","article-title":"Thrombosis, Translational Medicine, and Biomarker Research: Moving the Needle","volume":"14","author":"Shaw","year":"2025","journal-title":"J. Am. Heart Assoc."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/0049-3848(73)90084-4","article-title":"Subunit relationships between fibrinogen and fibrin degradation products","volume":"2","author":"Gaffney","year":"1973","journal-title":"Thromb. Res."},{"key":"ref_46","first-page":"59","article-title":"Prevalence of and Risk Factors for Venous Thromboembolism in Patients with Lymphoma: A Meta-Analysis","volume":"51","author":"Jiang","year":"2023","journal-title":"Oncol. Nurs. Forum"},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"He, C., Wang, Y., Zhang, H., Li, S., Kang, F., Cai, F., Han, L., Yin, Q., Li, G., and Song, X. (2025). A study on a real-world data-based VTE risk prediction model for lymphoma patients. Front. Pharmacol., 16.","DOI":"10.3389\/fphar.2025.1691271"},{"key":"ref_48","unstructured":"Zivkovic, E., Mitrovic-Ajtic, O., Suboticki, T., Ivanovic, J., Otasevic, V., Dikic, D., Diklic, M., Vukotic, M., Dragojevic, T., and Stanisavljevic, D. (2025). Thromboinflammatory Biomarkers in Lymphomas: Linking Inflammation to Thrombosis Risk. Int. J. Mol. Sci., 26."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Nguyen, T.T.H., Do, H.N., Le, T.Y., Nguyen, T.T., Nguyen, T.L., and Le, V.Q. (2025). Venous thromboembolism risk in newly diagnosed lymphoma patients: A real-world prospective observational study from Vietnam National Cancer Hospital. BMC Cancer, 25.","DOI":"10.1186\/s12885-025-14719-3"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.thromres.2018.01.037","article-title":"Laboratory biomarkers for venous thromboembolism risk in patients with hematologic malignancies: A review","volume":"163","author":"Konkle","year":"2018","journal-title":"Thromb. Res."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1200\/JCO.2010.32.8294","article-title":"Prediction of venous thromboembolism in patients with cancer by measuring thrombin generation: Results from the Vienna Cancer and Thrombosis Study","volume":"29","author":"Ay","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s12959-022-00381-3","article-title":"Immune activation and inflammatory biomarkers as predictors of venous thromboembolism in lymphoma patients","volume":"20","author":"Otasevic","year":"2022","journal-title":"Thromb. J."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1182\/blood.2020005861","article-title":"Neutrophil extracellular traps promote fibrous vascular occlusions in chronic thrombosis","volume":"137","author":"Sharma","year":"2021","journal-title":"Blood"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"7056","DOI":"10.1182\/bloodadvances.2023011379","article-title":"Impaired fibrinolysis and increased clot strength are potential risk factors for thrombosis in lymphoma","volume":"7","author":"Bonlokke","year":"2023","journal-title":"Blood Adv."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2703","DOI":"10.1182\/blood-2008-02-142422","article-title":"High plasma levels of soluble P-selectin are predictive of venous thromboembolism in cancer patients: Results from the Vienna Cancer and Thrombosis Study (CATS)","volume":"112","author":"Ay","year":"2008","journal-title":"Blood"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.3324\/haematol.2011.054718","article-title":"High D-dimer levels are associated with poor prognosis in cancer patients","volume":"97","author":"Ay","year":"2012","journal-title":"Haematologica"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1177\/10781552211004705","article-title":"Assessing the risk of venous thromboembolism (VTE) in ambulatory patients with cancer: Rationale and implementation of a pharmacist-led VTE risk assessment program in an ambulatory cancer centre","volume":"27","author":"Pelletier","year":"2021","journal-title":"J. Oncol. Pharm. Pract."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Riondino, S., Ferroni, P., Zanzotto, F.M., Roselli, M., and Guadagni, F. (2019). Predicting VTE in Cancer Patients: Candidate Biomarkers and Risk Assessment Models. Cancers, 11.","DOI":"10.3390\/cancers11010095"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1200\/JCO.2008.21.7752","article-title":"D-dimer and prothrombin fragment 1 + 2 predict venous thromboembolism in patients with cancer: Results from the Vienna Cancer and Thrombosis Study","volume":"27","author":"Ay","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1001\/archinte.160.6.809","article-title":"Risk factors for deep vein thrombosis and pulmonary embolism: A population-based case-control study","volume":"160","author":"Heit","year":"2000","journal-title":"Arch. Intern. Med."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1200\/JCO.19.01461","article-title":"Venous Thromboembolism Prophylaxis and Treatment in Patients with Cancer: ASCO Clinical Practice Guideline Update","volume":"38","author":"Key","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"7585","DOI":"10.1002\/cam4.4280","article-title":"Incorporating genetic and clinical data into the prediction of thromboembolism risk in patients with lymphoma","volume":"10","author":"Ortiz","year":"2021","journal-title":"Cancer Med."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1002\/ajh.25837","article-title":"Aggressive lymphoma subtype is a risk factor for venous thrombosis. Development of lymphoma\u2014Specific venous thrombosis prediction models","volume":"95","author":"Dharmavaram","year":"2020","journal-title":"Am. J. Hematol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1111\/jth.14824","article-title":"The Khorana score for prediction of venous thromboembolism in cancer patients: An individual patient data meta-analysis","volume":"18","author":"Ventresca","year":"2020","journal-title":"J. Thromb. Haemost."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"e289","DOI":"10.1016\/S2352-3026(18)30063-2","article-title":"A clinical prediction model for cancer-associated venous thromboembolism: A development and validation study in two independent prospective cohorts","volume":"5","author":"Pabinger","year":"2018","journal-title":"Lancet Haematol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"2926","DOI":"10.1200\/JCO.22.01542","article-title":"Derivation and Validation of a Clinical Risk Assessment Model for Cancer-Associated Thrombosis in Two Unique US Health Care Systems","volume":"41","author":"Li","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"10760296211045908","DOI":"10.1177\/10760296211045908","article-title":"The Application of the ThroLy Risk Assessment Model to Predict Venous Thromboembolism in Patients with Diffuse Large B-Cell Lymphoma","volume":"27","author":"Mansour","year":"2021","journal-title":"Clin. Appl. Thromb. Hemost."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1002\/ajh.27335","article-title":"Thrombosis risk prediction in lymphoma patients: A multi-institutional, retrospective model development and validation study","volume":"99","author":"Ma","year":"2024","journal-title":"Am. J. Hematol."},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Pan, L., Lin, W., Qiu, Y., Chen, J., Li, N., and Liu, T. (2025). Development and internal validation of a lymphoma-specific nomogram for predicting venous thromboembolism: A retrospective cohort of 790 patients. BMC Cancer, 25.","DOI":"10.1186\/s12885-025-15162-0"},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Jiang, T., Yang, Z., Tang, X., Fan, N., Hu, Z., Li, J., Liu, T., Peng, Y., Chen, S., and Guo, B. (2025). Development and validation of a machine learning-based early warning system for predicting venous thromboembolism risk in hospitalized lymphoma patients undergoing chemotherapy: A multicenter and retrospective cohort study. Front. Oncol., 15.","DOI":"10.3389\/fonc.2025.1566905"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1634\/theoncologist.2016-0246","article-title":"Preventing Venous Thromboembolism in Ambulatory Cancer Patients: The ONKOTEV Study","volume":"22","author":"Cella","year":"2017","journal-title":"Oncologist"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1038\/s41416-018-0027-8","article-title":"Multivariable clinical-genetic risk model for predicting venous thromboembolic events in patients with cancer","volume":"118","author":"Ortega","year":"2018","journal-title":"Br. J. Cancer"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1182\/bloodadvances.2020003442","article-title":"American Society of Hematology 2021 guidelines for management of venous thromboembolism: Prevention and treatment in patients with cancer","volume":"5","author":"Lyman","year":"2021","journal-title":"Blood Adv."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/rth2.12111","article-title":"Management of anticoagulation for cancer-associated thrombosis in patients with thrombocytopenia: A systematic review","volume":"2","author":"Lee","year":"2018","journal-title":"Res. Pract. Thromb. Haemost."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.annonc.2022.12.014","article-title":"Venous thromboembolism in cancer patients: ESMO Clinical Practice Guideline","volume":"34","author":"Falanga","year":"2023","journal-title":"Ann. Oncol."},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Frere, C., Benzidia, I., Marjanovic, Z., and Farge, D. (2019). Recent Advances in the Management of Cancer-Associated Thrombosis: New Hopes but New Challenges. Cancers, 11.","DOI":"10.3390\/cancers11010071"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1056\/NEJMoa1711948","article-title":"Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism","volume":"378","author":"Raskob","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1056\/NEJMoa1915103","article-title":"Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer","volume":"382","author":"Agnelli","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/jth.14662","article-title":"Apixaban and dalteparin in active malignancy-associated venous thromboembolism: The ADAM VTE trial","volume":"18","author":"McBane","year":"2020","journal-title":"J. Thromb. Haemost."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1200\/JCO.2018.78.8034","article-title":"Comparison of an Oral Factor Xa Inhibitor with Low Molecular Weight Heparin in Patients with Cancer with Venous Thromboembolism: Results of a Randomized Trial (SELECT-D)","volume":"36","author":"Young","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1200\/JCO.23.00294","article-title":"Venous Thromboembolism Prophylaxis and Treatment in Patients with Cancer: ASCO Guideline Update","volume":"41","author":"Key","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"483","DOI":"10.6004\/jnccn.2024.0046","article-title":"Cancer-Associated Venous Thromboembolic Disease, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology","volume":"22","author":"Streiff","year":"2024","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1814468","article-title":"Apixaban to Prevent Venous Thromboembolism in Patients with Cancer","volume":"380","author":"Carrier","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1056\/NEJMoa1814630","article-title":"Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer","volume":"380","author":"Khorana","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"e566","DOI":"10.1016\/S1470-2045(19)30336-5","article-title":"2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer","volume":"20","author":"Farge","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_86","first-page":"113","article-title":"The 2022 ITAC evidence-based clinical practice guidelines: New update from the International Initiative on Thrombosis and Cancer to improve the care in patients with cancer-associated thrombosis","volume":"47","author":"Frere","year":"2022","journal-title":"J. Med. Vasc."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.thromres.2020.02.005","article-title":"Patient characteristics and long-term outcomes beyond the first 6 months after a diagnosis of cancer-associated venous thromboembolism","volume":"188","author":"Schmidt","year":"2020","journal-title":"Thromb. Res."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1182\/blood.2019003689","article-title":"How I treat and prevent venous thrombotic complications in patients with lymphoma","volume":"139","author":"Schmidt","year":"2022","journal-title":"Blood"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1056\/NEJMoa2416112","article-title":"Extended Reduced-Dose Apixaban for Cancer-Associated Venous Thromboembolism","volume":"392","author":"Mahe","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_90","first-page":"171","article-title":"Platelet cut-off for anticoagulant therapy in thrombocytopenic patients with blood cancer and venous thromboembolism: An expert consensus","volume":"17","author":"Napolitano","year":"2018","journal-title":"Blood Transfus."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1056\/NEJMc1806646","article-title":"Edoxaban for Cancer-Associated Venous Thromboembolism","volume":"379","author":"Raskob","year":"2018","journal-title":"N. Engl. J. Med."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/12\/5461\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T08:28:15Z","timestamp":1781684895000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/12\/5461"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,17]]},"references-count":91,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["ijms27125461"],"URL":"https:\/\/doi.org\/10.3390\/ijms27125461","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,17]]}}}